On February 20th, global flavor and fragrance giant IFF announced its financial results for the fourth quarter and full year of 2023. As of December 31st, IFF achieved a net sales of $11.479 billion for the year 2023, representing an 8% decline compared to the previous year. The operating loss was $2.11 billion, compared to a loss of $1.326 billion in the same period last year.
IFF attributed the decline in sales primarily to the weakness in the Nourish and Pharma Solutions Segment, which offset the growth in the Scent and Health & Biosciences Segment. Additionally, IFF reported a full-year pre-tax loss of $2.518 billion, mainly due to a non-cash impairment charge of $2.6 billion.
In terms of quarterly performance, IFF’s net sales for the fourth quarter were $2.703 billion, a 5% year-on-year decline. On a comparable basis, excluding currency factors, the sales increased by 1% year-on- year. The adjusted EBITDA for the quarter was $461 million.
Looking at the overall performance of different segments, only the Scent Segment saw an increase in sales and profits for the year 2023. The Nourish, Health & Biosciences, and Pharma Solutions Segment all experienced declines.
Specifically, Scent Segment recorded sales of $578 million in the fourth quarter and achieved $2.39 billion for the full year 2023. This growth was mainly driven by double-digit increases in consumer fragrances and prestige fragrances. On a comparable basis, excluding currency factors, the sales increased by 8%. The adjusted operating EBITDA for the full year was $461 million, with an adjusted operating EBITDA margin of 19.3%.
Furthermore, the Pharma Solutions, Nourish, and Health & Biosciences divisions reported sales of $945 million, $6.06 billion, and $2.08 billion, respectively, in 2023.
Looking ahead to 2024, IFF expects full-year sales to be in the range of $10.8 billion to $11.1 billion, and adjusted EBITDA to be in the range of $1.9 billion to $2.1 billion.
Considering the ongoing macroeconomic uncertainty, IFF anticipates a 0% to 3% decrease in volumes, with an overall improvement in the trend for most product portfolios. Pricing is expected to decrease by approximately 2.5% due to lower costs of input and competitive dynamics, primarily influenced by declining prices of functional and flavor ingredients. Based on current market exchange rates, the company expects foreign exchange to have a 0% to 1% adverse impact on sales growth in 2024.
